17,261 trials
Rheumatoid Arthritis
Primary: Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to…
Psoriasis Vulgaris
Primary: Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate…
Healthy · Obesity · Overweight
Primary: Insulin iAUC Obtained During the Oral Glucose Tolerance Test at the Final Experimental Visit. — 13,698.60; 10,619.70 mIU/dL∙min — p=0.005
Carcinoma, Squamous Cell of Head and Neck
Primary: Phase I - Maximum Tolerated Dose (MTD) — NA mg
Multiple Sclerosis
Primary: Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24 — 1.4; 1.1; 3.5; 6.2 Lesions — p=<0.0001
Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myeloproliferative Disorder
Primary: Full-dose Donor Chimerism (FDC) at Day 28 Following TLI/ATG/TBI Conditioning. — 13 Participants
Stage III Cutaneous Melanoma · Stage IIIA Cutaneous Melanoma · Stage IIIB Cutaneous Melanoma
Primary: Objective Response Rate (ORR) — 0.522 proportion of participants
Pulmonary Hypertension · Sickle Cell Disease · Thalassemia
Primary: Erythrocyte Glutamine/Glutamate Ratio at 8 Weeks — 2.40 Ratio
Tuberculosis
Primary: Mycobacterium Tuberculosis (MTB) Infection — 10; 18 participants
Systemic Sclerosis · Calcinosis
Primary: Number of Participants With Treatment-related Adverse Events Following Treatment With Oral Treprostinil — 11 Participants
Stimulant Use & Co-occuring Opioid Use Disorders
Primary: Number of Participants With Stimulant Positive Drug Screen — 9; 12; 9; 10 Participants
Venous Thormboembolism
Primary: Total Number of Venous Thromboembolic Events (VTE) in Standard Dose Enoxaparin Arm at 17 Days — 2 participants
Healthy Volunteers
Primary: Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding…
Leukemia
Primary: Overall Survival (OS) — 7.5 Months
Sjogren's Syndrome
Primary: Number of Participants With Serious Adverse Events (SAE) and Non-serious AEs (Non-SAE) — 0; 3; 2; 4 Participants